argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include Efgartigimod (ARGX-113) that completed Phase II clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy; and Cusatuzumab (ARGX-110), which is in Phase I/II clinical trials for the treatment of acute myeloid leukemia and T-cell lymphoma. It is also developing ARGX-117 for the treatment of severe autoimmune diseases; ARGX-111 to treat solid tumors; ARGX-112 to treat dermatologic indications; ARGX-115, a cancer immunotherapy-focused product candidate against the glycoprotein A repetitions predominant; ARGX-116 for the treatment of dyslipidemia; and ARGX-109 for the treatment of rheumatoid arthritis. The company has license and collaboration agreements with AbbVie S.Á.R.L.; Cilag GmbH International; Bird Rock Bio, Inc.; LEO Pharma A/S; Staten Biotechnology B.V.; and Shire International GmbH. argenx SE was founded in 2008 and is based in Breda, the Netherlands.